Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

TARRYTOWN, N.Y. and BERLIN, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).  In this trial, 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams (mg) monthly gained at least 15 letters of vision from baseline, compared to 12.3 percent of patients receiving sham injections (p<0.0001), the primary endpoint of the study.  Patients receiving VEGF Trap-Eye 2mg monthly gained, on average, 17.3 letters of vision compared to a mean loss of 4.0 letters with sham injections (p<0.001), a secondary endpoint.  The second Phase 3 study, GALILEO, is currently ongoing and is led by Bayer HealthCare.

VEGF Trap-Eye was generally well tolerated and the most common adverse events were those typically associated with intravitreal injections or the underlying disease.  A total of 114 patients were randomized to receive VEGF Trap-Eye and 73 patients to the control arm.  Serious ocular adverse events in the VEGF Trap-Eye group were uncommon (3.5%) and were more frequent in the control group (13.5%).  The incidence of non-ocular serious adverse events was generally well-balanced between the treatment arms.  There were no deaths among the 114 patients treated with VEGF Trap-Eye and two in the 73 (2.7%) patients treated with sham injections.

"In the COPERNICUS trial, patients treated with VEGF Trap-Eye experienced a marked improvement in vision," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories.  "If these results are confirmed by data from the GALILEO study, expected in the second quarter of 2
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 3, 2015  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... treating opioid overdose with intranasal naloxone, has commenced ... (NDA) to the United States Food and Drug ... naloxone, a drug intended to treat opioid overdose. ...
(Date:6/3/2015)...  The International Confederation of Midwives (ICM) has provided ... a standard for midwives trained to ICM,s competency standards.  ... consultation with ICM experts. Direct Relief will provide the ... As many as one in 30 women ... childbirth.  Skilled birth attendants such as midwives offer the ...
(Date:6/3/2015)... 2015 According to a ... Vascular Devices Market (Embolic Protection, Chronic Total Occlusion, ... IVC Filters, Stents, Balloons and Accessories) - Forecasts ... and Peripheral Vascular Devices Market is expected to ... CAGR of 7.4% from 2014 to 2019. ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 4The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4
... Dec. 29, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... announcement by the U.S. Food and Drug Administration (FDA) ... transmucosal fentanyl products has been approved.  The program, which ... Fentanyl (TIRF) REMS Access Program, was designed to ensure ...
... ESRX ) announced that it will present at ... 2012 at 9:00 a.m. PST (12:00 p.m. EST) at the ... The presentation will also be broadcast via the Internet and ... Scripts web site at http://www.express-scripts.co m .  RealPlayer ...
Cached Medicine Technology:ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 2ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 3ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 4
(Date:6/3/2015)... (PRWEB) June 03, 2015 A ... additional precautions on product labels underscores the importance ... according to the American Society for Dermatologic Surgery ... include new warnings about the risks for serious ... vessels. While product labels already include information about ...
(Date:6/3/2015)... Loma Linda University Health and Adventist ... Gorgonio Memorial Hospital (SGMH). The SGMH board voted unanimously ... , “Loma Linda University Health has been serving the ... executive officer, Loma Linda University Medical Center. “We are ... to this community.” , Under the proposed affiliation, ...
(Date:6/3/2015)... June 03, 2015 Johnson & Johnson ... $7.8 million to resolve a Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... the company allegedly used to market the antipsychotic drug. ... indicate that the Arkansas Attorney General moved to dismiss ... accord. The Risperdal settlement amounts to just a fraction ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 The ... to announce that Maria C. Savoia, M.D., Dean of Medical ... of Medicine, will become Chair on July 1. ... Chair of the National Resident Matching Program,” said Dr. Savoia. ... reliable process for matching medical students with training programs, and ...
(Date:6/3/2015)... On the heels of a report predicting ... 2020 ( click here to review news coverage about ... Baltimore has the talent to become a world-leading center ... and other biological data are collected and analyzed to help ... all the elements of a perfect storm for bioinformatics leadership,” ...
Breaking Medicine News(10 mins):Health News:ASDSA Supports FDA Fillers Directive 2Health News:ASDSA Supports FDA Fillers Directive 3Health News:ASDSA Supports FDA Fillers Directive 4Health News:Loma Linda University Health and Adventist Health Enter into Exclusive Affiliation Negotiations with San Gorgonio Memorial Hospital 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3
... stage III colon cancer treated with 5-FU-based chemotherapy after ... improved overall survival with no change in time to ... patients with stage II colon cancer treated after 1995 ... to death compared to those patients treated prior to ...
... ... Days of Intentions to mark the mid-point of 2010. , ... Los Angeles, CA (PRWEB) June 3, 2010 -- This week, Intent.com launches ... Days of Intentions is a challenge to the internet community to commit to posting one new ...
... Davis public health researchers have found that children, who ... choices, are the targets of a new medium used ... an entertaining blend of interactive animation, video content and ... online messages that primarily promote corporate branding and products. ...
... high school, study finds , THURSDAY, June 3 (HealthDay News) ... the two years following high school are less likely to ... , The finding builds on past research that had demonstrated ... and alcohol abuse. , "I,m not saying that we should ...
... but others say it,s not always that simple, , THURSDAY, ... prompts anxiety in many a parent. But having to ... story can make an already sensitive subject even more complicated. ... parents. , As assisted reproduction technology, in which someone other ...
... ... ... 2010 -- Thomas D. Meade, M.D., a nationally renowned knee specialist who has performed ... June 1, Dr. Meade will see patients at Coordinated Health facilities in Allentown, Bethlehem, ...
Cached Medicine News:Health News:Stage II and stage III colon cancer patients treated after 1995 have improved overall survival 2Health News:Intent.com Launches 30 Days of Intentions and Announces Winners of 2010 Intent Web Awards 2Health News:Online games new marketing tool for unhealthy foods 2Health News:Online games new marketing tool for unhealthy foods 3Health News:Romance May Steer Young Adults Away From Booze, Pot 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 3Health News:Nationally Renowned Knee Specialist Dr. Thomas Meade Joins Coordinated Health 2Health News:Nationally Renowned Knee Specialist Dr. Thomas Meade Joins Coordinated Health 3
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Medicine Products: